HISTOPATHOLOGY AND MOLECULAR PATHOLOGY

组织病理学和分子病理学

• 批准号: 6269110
• 负责人: PELAYO none CORREA
• 金额: $ 30.92万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-03-01 至 1999-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6269110
• 关键词: DNA damage; Helicobacter; antibacterial agents; antioxidants; biomarker; biopsy; cell cycle; clinical research; gastric mucosa; gastritis; gastrointestinal epithelium; gastrointestinal neoplasms; gene expression; gene rearrangement; histopathology; human subject; immunoperoxidase; metaplasia; molecular oncology; mucins; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; oxidative stress; preneoplastic state; tumor suppressor genes

This project evaluates the endpoints to determine the status and the evolution of the lesions of the gastric mucosa utilizing histopathological, immunochemical and molecular biology techniques. Biopsies taken from 8 specific locations in the gastric mucosa in patients from Colombia and New Orleans will be assigned a global diagnosis based on the most advanced lesion and detailed assessment of the following parameters" polymorphonuclear, and mononuclear leukocytic infiltration, damage to epithelial cells, atrophy, metaplasia, mucins, Lewis antibodies, Ki 67 labelling index, inducible nitric oxide synthase, nitrotyrosine, apoptosis, p53 abnormalities, TPR-MET expression and microsatellite destabilization. The techniques for the utilization of these markers are described in the text and are thoroughly familiar to the investigators. The different interventions described in the other projects, especially anti-Helicobacter pylori therapy and administration of antioxidants are directed to modify the phenotypic events in the precancerous process. The markers chosen are intended to evaluate those changes with state of the art techniques in pre- and post-intervention biopsies. Each marker will be evaluated independently and combinations of them will be designed and tested to develop measures of change of the precancerous process in terms of single and combined scores.

该项目评估终点以确定状态和 利用组织病理学的胃粘膜病变的进化， 免疫化学和分子生物学技术。 活检从8种 来自哥伦比亚和新患者的胃粘膜中的特定位置 奥尔良将根据最先进的 病变和详细评估以下参数” 多形核和单核白细胞浸润，损害 上皮细胞，萎缩，化生，粘蛋白，刘易斯抗体，Ki 67 标记指数，诱导型一氧化氮合酶，硝基酪氨酸，凋亡，凋亡， p53异常，TPR-MET表达和微卫星不稳定。 这些标记的利用技术在 文字并非常熟悉调查员。 不同的 其他项目中描述的干预措施，尤其是反螺旋细菌 幽门疗法和抗氧化剂的给药可用于修饰 癌前过程中的表型事件。 选择的标记是 旨在评估这些变化，并以前的技术技术 和干预后活检。 每个标记将评估 独立并将其组合设计和测试 根据单一制定癌前过程的变化度量 和组合得分。